keyword
MENU ▼
Read by QxMD icon Read
search

Progestin

keyword
https://www.readbyqxmd.com/read/27932442/contraceptive-sales-in-the-setting-of-the-zika-virus-epidemic
#1
Luis Bahamondes, Moazzam Ali, Ilza Monteiro, Arlete Fernandes
STUDY QUESTION: Has there been any influence of the Zika virus (ZIKV) outbreak on the sales of contraceptive methods in Brazil? SUMMARY ANSWER: Contraceptive sales in the 24 months of evaluation showed little variation and no significant change has been observed since the ZIKV outbreak. WHAT IS KNOWN ALREADY: Transmission of ZIKV is primarily by Aedes aegypti mosquitoes; however, sexual transmission has also been described. The association of several birth defects and the ZIKV infection during pregnancy has been established, and it was estimated in Bahia, Brazil that the infection rate could range from 10% to 80%...
December 7, 2016: Human Reproduction
https://www.readbyqxmd.com/read/27924667/contraceptive-practices-in-women-with-sickle-cell-disease
#2
Natália S Carvalho, Josefina Pellegrini Braga, Márcia Barbieri, Maria R Torloni, Maria S Figueiredo, Cristina A F Guazzelli
This was a cross-sectional study of sexually active women with sickle-cell disease (SCD) managed at São Paulo Federal University during a one-year period. A total of 54 women were included. Mean age was 32.0 (11.2, standard deviation) years and almost 95% were black or of mixed racial ancestry. Almost 80% reported a history of multiple blood transfusions, 50% had kidney disease and 17% had a history of thrombosis. Over 80% of them had used some form of contraception, mostly combined hormonal contraceptive (52%) or progestin-only contraceptives (46%)...
December 7, 2016: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/27916205/efficacy-and-safety-of-transdermal-testosterone-in-postmenopausal-women-with-hypoactive-sexual-desire-disorder-a-systematic-review-and-meta-analysis
#3
Chiara Achilli, Jyotsna Pundir, Parimalam Ramanathan, Luca Sabatini, Haitham Hamoda, Nick Panay
OBJECTIVE: To systematically review and summarize the existing evidence related to the efficacy and safety of transdermal T in postmenopausal women for the treatment of hypoactive sexual desire disorder (HSDD). DESIGN: Systematic reviews and meta-analysis. SETTING: Not applicable. PATIENT(S): Seven randomized controlled trials enrolled 3,035 participants; 1,350 women were randomized to treatment with T patch, and 1,379 women were randomized to placebo...
December 1, 2016: Fertility and Sterility
https://www.readbyqxmd.com/read/27911853/recurrence-of-cervical-cancer-and-its-resistance-to-progestin-therapy-in-a-mouse-model
#4
Fabiola F Mehta, Seunghan Baik, Sang-Hyuk Chung
Studies using K14E6/K14E7 transgenic mice expressing E6 and E7 oncoprotein of human papillomavirus type 16 (HPV16) have demonstrated that estrogen (E2) is required for the genesis and growth of cervical cancer. Our prior study using the same mouse model has showed that progestin drug medroxyprogesterone acetate (MPA) promotes regression of primary cervical cancer. In the present study, we use the same transgenic mouse model to determine whether the cancer recurs after MPA therapy. Cervical cancer recurred even if MPA treatment was continued...
November 29, 2016: Oncotarget
https://www.readbyqxmd.com/read/27908210/the-sexuological-impact-of-hormonal-contraceptives-based-on-their-route-of-administration
#5
Maurizio Guida, Costantino Di Carlo, Jacopo Troisi, Alessandra Gallo, Francesca Cibarelli, Ellis Martini, Lara Tiranini, Rossella E Nappi
Evidence on the effects of hormonal contraceptives on female sexuality is conflicting. We enrolled 556 women, divided into six groups: two composed of subjects using a combined hormonal contraceptive (COC) containing 0.020 ("COC20") and 0.030 ("COC30") mg of ethynyl estradiol (EE), "natural", using COC containing 1.5 mg of estradiol (E2), "ring", using a vaginal ring releasing each day 0.015 mg of EE + 0.120 of etonogestrel, "subcutaneous", using a progestin only subcutaneous contraceptive implant releasing etonogestrel and "controls", using no hormonal contraceptive methods...
December 2, 2016: Gynecological Endocrinology
https://www.readbyqxmd.com/read/27907851/effects-of-antiandrogenic-progestins-chlormadinone-and-cyproterone-acetate-and-the-estrogen-17%C3%AE-ethinylestradiol-ee2-and-their-mixtures-transactivation-with-human-and-rainbowfish-hormone-receptors-and-transcriptional-effects-in-zebrafish-danio-rerio-eleuthero
#6
Patricia Franziska Siegenthaler, Peter Bain, Francesco Riva, Karl Fent
Synthetic progestins act as endocrine disrupters in fish but their risk to the environment is not sufficiently known. Here, we focused on an unexplored antiandrogenic progestin, chlormadinone acetate (CMA), and the antiandrogenic progestin cyproterone acetate (CPA). The aim was to evaluate whether their in vitro interaction with human and rainbowfish (Melanotaenia fluviatilis) sex hormone receptors is similar. Furthermore, we investigated their activity in zebrafish (Danio rerio) eleuthero-embryos. First, we studied agonistic and antagonistic activities of CMA, CPA, and 17α-ethinylestradiol (EE2), in recombinant yeast expressing either the human progesterone (PGR), androgen (AR), or estrogen receptor...
November 9, 2016: Aquatic Toxicology
https://www.readbyqxmd.com/read/27906568/lower-death-risk-for-vascular-dementia-than-for-alzheimer-s-disease-with-postmenopausal-hormone-therapy-users
#7
Tomi S Mikkola, Hanna Savolainen-Peltonen, Pauliina Tuomikoski, Fabian Hoti, Pia Vattulainen, Mika Gissler, Olavi Ylikorkala
CONTEXT: There are conflicting data on postmenopausal hormone therapy (HT) and the risk of vascular dementia (VD) and Alzheimer's disease (AD). OBJECTIVE: We analyzed the mortality risk attributable to VD or AD in women with a history of HT use. Design, Patients, Interventions and Main Outcome Measures: A total of 489,105 Finnish women using systemic HT in 1994-2009 were identified from the nationwide drug reimbursement register. Of these women, 581 died of VD and 1057 of AD in 1998-2009...
December 1, 2016: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27905115/treatment-for-hereditary-angioedema-with-normal-c1-inh-and-specific-mutations-in-the-f12-gene-hae-fxii
#8
K Bork, K Wulff, G Witzke, J Hardt
Hereditary angioedema with normal C1 esterase inhibitor and mutations in the F12 gene (HAE-FXII) is associated with skin swellings, abdominal pain attacks, and the risk of asphyxiation due to upper airway obstruction. It occurs nearly exclusively in women. We report our experience treating HAE-FXII with discontinuation of potential trigger factors and drug therapies. The study included 72 patients with HAE-FXII. Potential triggers included estrogen-containing oral contraceptives (eOC), hormonal replacement therapy, or angiotensin-converting enzyme inhibitors...
November 6, 2016: Allergy
https://www.readbyqxmd.com/read/27904953/endometrial-preparation-with-dienogest-before-hysteroscopic-surgery-a-systematic-review
#9
Antonio Simone Laganà, Salvatore Giovanni Vitale, Vincenzo Muscia, Paola Rossetti, Massimo Buscema, Onofrio Triolo, Agnese Maria Chiara Rapisarda, Loretta Giunta, Vittorio Palmara, Roberta Granese, Helena Ban Frangež, Andrea Romano
PURPOSE: Hysteroscopic surgery is considered the gold standard for the minimal invasive treatment of many endouterine diseases such as endometrial polyps or submucous myomas. Recently, many studies have evaluated the effect of preoperative administration of a number of drugs to reduce endometrial thickness and achieve important intraoperative advantages. The purpose of this systematic review is to summarize the available evidence about the use of Dienogest, an orally administrable progestin, for endometrial preparation before hysteroscopic surgery...
November 30, 2016: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/27899496/hormonal-contraception-and-risk-of-thromboembolism-in-women-with-diabetes
#10
Sarah H O'Brien, Terah Koch, Sara K Vesely, Eleanor Bimla Schwarz
OBJECTIVE: To investigate safety of hormonal contraception with regard to thromboembolic events in women with type 1 or 2 diabetes. RESEARCH DESIGN AND METHODS: We used data from 2002-2011 in Clinformatics Data Mart to identify women in the U.S., 14-44 years of age, with an ICD-9-CM code for diabetes and a prescription for a diabetic medication or device. We examined contraceptive claims and compared time to thromboembolism (venous thrombosis, stroke, or myocardial infarction) among women with diabetes dispensed hormonal contraception using a modification of Cox regression to control for age, smoking, obesity, hypertension, hyperlipidemia, diabetic complications, and history of cancer; we excluded data for 3 months after women gave birth...
November 29, 2016: Diabetes Care
https://www.readbyqxmd.com/read/27892938/dendritic-cell-function-and-pathogen-specific-t-cell-immunity-are-inhibited-in-mice-administered-levonorgestrel-prior-to-intranasal-chlamydia-trachomatis-infection
#11
Nirk E Quispe Calla, Rodolfo D Vicetti Miguel, Ao Mei, Shumin Fan, Jocelyn R Gilmore, Thomas L Cherpes
The growing popularity of levonorgestrel (LNG)-releasing intra-uterine systems for long-acting reversible contraception provides strong impetus to define immunomodulatory properties of this exogenous progestin. In initial in vitro studies herein, we found LNG significantly impaired activation of human dendritic cell (DCs) and their capacity to promote allogeneic T cell proliferation. In follow-up studies in a murine model of intranasal Chlamydia trachomatis infection, we analogously found that LNG treatment prior to infection dramatically reduced CD40 expression in DCs isolated from draining lymph nodes at 2 days post infection (dpi)...
November 28, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27889055/medical-or-surgical-management-of-fibroids-an-internet-survey-of-gynecologists-views
#12
Elisa Pazzaglia, Julie Praet, Jean Vandromme, Serge Rozenberg
AIM: To assess the attitudes of gynecologists toward symptomatic fibroids and analyze which factors influence their choice of treatment. MATERIAL AND METHOD: We surveyed the attitude of Belgian gynecologists toward patients' cases. We used a vignette of a woman with symptomatic fibroids and modified 3 factors: her age, her parity and her desire for pregnancy, thereby establishing 12 different cases. We ensured that each gynecologist (n=1437) received one case, chosen randomly, by email...
January 2017: Maturitas
https://www.readbyqxmd.com/read/27889052/types-of-oral-contraceptives-and-breast-cancer-survival-among-women-enrolled-in-medicaid-a-competing-risk-model
#13
Marsha E Samson, Swann Arp Adams, Caroline M Mulatya, Jiajia Zhang, Charles L Bennett, James Hebert, Susan E Steck
INTRODUCTION: Oral contraceptive pills have been implicated in the pathophysiology of breast cancer. Although many studies have examined the relationship between combined oral contraceptives (COCs) and breast cancer, there is a paucity of literature that discusses progestin-only oral contraceptives (POCs) and breast cancer. The purpose of this investigation is to examine potential associations between different types of oral contraceptives and breast cancer mortality in the South Carolina Medicaid population among different racial/ethnic groups...
January 2017: Maturitas
https://www.readbyqxmd.com/read/27887710/supplementation-with-progestogens-in-the-first-trimester-of-pregnancy-to-prevent-miscarriage-in-women-with-unexplained-recurrent-miscarriage-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#14
Gabriele Saccone, Corina Schoen, Jason M Franasiak, Richard T Scott, Vincenzo Berghella
OBJECTIVE: To investigate whether treatment with progestogens in the first trimester of pregnancy would decrease the incidence of miscarriage in women with a history of unexplained recurrent miscarriage. DESIGN: Systematic review and meta-analysis. SETTING: Not applicable. PATIENT(S): Women with a history of unexplained recurrent miscarriage. INTERVENTION(S): Randomized, controlled trials were identified by searching electronic databases...
November 22, 2016: Fertility and Sterility
https://www.readbyqxmd.com/read/27861709/contraceptive-use-in-the-nordic-countries
#15
Ingela Lindh, Finn Egil Skjeldestad, Kristina Gemzell-Danielsson, Oskari Heikinheimo, Helena Hognert, Ian Milsom, Øjvind Lidegaard
The aim was to compare contraceptive use in the Nordic countries and to assess compliance with recommendations from the European Medicines Agency regarding the use of combined oral contraceptives (COC) containing low dose estrogen and levonorgestrel, norethisterone or norgestimate MATERIAL AND METHODS: Data on hormonal contraceptive prescriptions and sales figures for copper intrauterine devices (Cu-IUD) were obtained from national databases and manufacturers in Denmark, Finland, Iceland, Norway and Sweden 2010-2013 RESULTS: Contraceptive use was highest in Denmark (42%) and Sweden (41%), followed by Finland (40%)...
November 12, 2016: Acta Obstetricia et Gynecologica Scandinavica
https://www.readbyqxmd.com/read/27843051/effect-of-hormone-replacement-therapy-with-the-anti-mineralocorticoid-progestin-drospirenone-compared-to-tibolone-on-endothelial-function-and-central-haemodynamics-in-post-menopausal-women
#16
Cristiana Vitale, Caterina Mammi, Marco Gambacciani, Novella Russo, Ilaria Spoletini, Massimo Fini, Maurizio Volterrani, Giuseppe M C Rosano
Drospirenone (DRSP) is an antialdosterone agent with progestogenic and antiandrogenic effects. This compound, has been recently used in combination with 17β-estradiol (E2) as hormonal therapy in postmenopausal women and has been shown to exert a significant antihypertensive effect in hypertensive post-menopausal women. Aim of the present study was to compare the effect of DRSP/E2 with those of Tibolone (T) on endothelial function, arterial stiffness, and lipid profile of early postmenopausal women naïve on post-menopausal hormonal therapy...
November 9, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27836505/a-randomized-clinical-trial-on-the-effects-of-progestin-contraception-in-the-genital-tract-of-hiv-infected-and-uninfected-women-in-lilongwe-malawi-addressing-evolving-research-priorities
#17
Athena P Kourtis, Lisa Haddad, Jennifer Tang, Lameck Chinula, Stacey Hurst, Jeffrey Wiener, Sascha Ellington, Julie A E Nelson, Amanda Corbett, Kristina De Paris, Caroline C King, Mina Hosseinipour, Irving F Hoffman, Denise J Jamieson
Hormonal contraception is central in the prevention of unintended pregnancy; however there are concerns that certain methods may increase the risk of HIV acquisition and transmission. Hormonal contraceptives may modify the genital mucosa in several ways, however the mechanisms are incompletely understood. Few studies have examined genital HIV shedding prospectively before and after initiation of hormonal contraception. The effects of hormonal contraception on genital HIV shedding in the setting of antiretroviral therapy (ART) are also unknown...
November 9, 2016: Contemporary Clinical Trials
https://www.readbyqxmd.com/read/27824503/nestorone%C3%A2-nes-a-novel-progestin-for-non-oral-contraception-structure-activity-relationships-and-brain-metabolism-studies
#18
Narender Kumar, Jerôme Fagart, Philippe Liere, Scott J Mitchell, Alanah R Knibb, Isabelle Petit-Topin, Marion Rame, Martine El-Etr, Michael Schumacher, Jeremy J Lambert, Marie-Edith Rafestin-Oblin, Regine Sitruk-Ware
Nestorone® (NES) is a highly potent non-androgenic progestin being developed for contraception. NES is a synthetic progestin that may possess neuroprotective and myelin regenerative potential as an added health benefits. In receptor transactivation experiments, NES displayed greater potency than progesterone to transactivate the human progesterone receptor (hPR). This was confirmed by docking experiments which revealed that NES adopts the same docking position within the PR ligand-binding domain (LBD) as progesterone and forms additional stabilizing contacts between 17α-acetoxy and 16-methylene groups and PR LBD supporting its higher potency than progesterone...
November 8, 2016: Endocrinology
https://www.readbyqxmd.com/read/27823750/clinical-audit-of-estradiol-implant-therapy-long-duration-of-action-and-implications-in-non-hysterectomised-women
#19
Shaday Wheatley, Robin J Bell, Bronwyn G A Stuckey, Penelope J Robinson, Susan R Davis
We audited the files of 114 postmenopausal women who had been treated with subcutaneous Estrapel (50mg oestradiol implants). Of the 92 women who received more than one implant, the median number of days between implants was 223.5 (range 49-875), with an estimated median time to return to baseline of 311days (range 108-1228). Although oestradiol implants can provide an excellent non-oral treatment option, their prolonged action makes patient selection important, as the implants cannot easily be removed. In women with an intact uterus, the continuation of progestin therapy after cessation of implant therapy is imperative...
December 2016: Maturitas
https://www.readbyqxmd.com/read/27817838/noncontraceptive-use-of-oral-combined-hormonal-contraceptives-in-polycystic-ovary-syndrome-risks-versus-benefits
#20
REVIEW
Anuja Dokras
The use of steroid sex hormones for noncontraceptive benefits has been endorsed by several medical societies. In women with polycystic ovary syndrome (PCOS), hormonal contraceptives are first-line therapy for concurrent treatment of menstrual irregularity, acne, and hirsutism. The association of PCOS with obesity, diabetes, and dyslipidemia frequently brings up the debate regarding risks versus benefits of hormonal contraceptives in this population. In women with PCOS, the lack of large-scale studies evaluating the risks with varying doses of ethinyl estradiol, types of progestins, and presence of confounding factors such as obesity, smoking, and other cardiometabolic comorbidities is a significant limitation in these deliberations...
December 2016: Fertility and Sterility
keyword
keyword
27346
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"